Surmodics (SRDX) Stock Price
Surmodics Price
Surmodics (SRDX) Stock | ISIN US8688731004 | WKN 914178. The current Surmodics stock price is 42.98 USD (2026). Revenue is 124.14 M USD. Net income is -2.79 M USD. The P/E ratio is -218.35. Market capitalization is 614.61 M USD. Surmodics operates in the Health sector.
Surmodics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Surmodics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Surmodics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Surmodics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Surmodics Price |
|---|
Surmodics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Surmodics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Surmodics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Surmodics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Surmodics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Surmodics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Surmodics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics business model & stock analysis
Surmodics SWOT Analysis
Strengths
- Established brand with a good reputation in the healthcare industry.
- Diverse portfolio of innovative medical devices and diagnostic products.
- Strong intellectual property rights, providing a competitive advantage.
- Solid financial position and consistent revenue growth.
Weaknesses
- Reliance on a limited number of major customers, posing a potential risk.
- Vulnerability to changes in government regulations and reimbursement policies.
- Limited global presence compared to some competitors.
- Potential product recalls or legal issues may impact reputation and financials.
Opportunities
- Growing demand for minimally invasive medical procedures, offering market expansion prospects.
- Increasing focus on personalized medicine and companion diagnostics.
- Potential partnerships and collaborations to enhance product offerings and market reach.
- Continuous advancements in medical technology present opportunities for product innovation.
Threats
- Intense competition from larger and more established companies.
- Economic downturns affecting healthcare spending and customer budget constraints.
- Rapidly evolving regulatory landscape impacting product development and market access.
- Potential disruptions in supply chain and manufacturing processes.
Surmodics Segments
Surmodics Revenue by Segment (1/3)
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
Surmodics Revenue by Segment (3/3)
3 Years
5 Years
Max
Details
Surmodics Eulerpool Fair Value
Surmodics historical P/E ratio, EBIT multiple, and P/S ratio
Surmodics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Surmodics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics Earnings Estimates
Surmodics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/28/2026 | -0.03USD | 31.06 MUSD | 2026 Q2 |
| 1/28/2026 | -0.13USD | 30.61 MUSD | 2026 Q1 |
| 11/6/2024 | -0.32USD | 31.01 MUSD | 2024 Q4 |
| 4/24/2024 | -0.39USD | 28.98 MUSD | 2024 Q2 |
| 2/5/2024 | -0.31USD | 30.24 MUSD | 2024 Q1 |
| 11/7/2023 | -0.57USD | 28.96 MUSD | 2023 Q4 |
| 7/25/2023 | -0.61USD | 27.45 MUSD | 2023 Q3 |
| 4/25/2023 | -0.62USD | 32.55 MUSD | 2023 Q2 |
| 2/1/2023 | -0.68USD | 24.33 MUSD | 2023 Q1 |
| 11/9/2022 | -0.46USD | 24.62 MUSD | 2022 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Surmodics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Surmodics shareholder structure
| % | Name |
|---|---|
7.1328% | |
5.94735% | |
5.66563% | |
5.5179% | |
5.21556% | |
5.01247% | |
3.03225% | |
2.95611% | |
2.7972% | |
2.75513% |
Surmodics Executives and Management Board
Mr. Gary Maharaj
(61)President, Chief Executive Officer, Director · since 2010
Ms. Teryl Sides
(55)Senior Vice President, President - Vascular Interventions
Mr. Timothy Arens
(57)Chief Financial Officer, Senior Vice President - Finance and Information Technology
Mr. Gordon Weber
(61)Senior Vice President - Legal, General Counsel, Secretary
Mr. Charles Olson
(60)Senior Vice President, President - Medical Device Coatings
Surmodics Supply Chain
Frequently asked questions about Surmodics
Surmodics Inc. is a medical technology company that operates through two segments: Medical Devices and In Vitro Diagnostics. The company's business model revolves around developing and commercializing innovative products and technologies that enhance the diagnosis and treatment of diseases. Surmodics' Medical Devices segment focuses on providing surface modification technologies to medical device manufacturers, enabling them to improve device performance and biocompatibility. On the other hand, the In Vitro Diagnostics segment offers proprietary diagnostic technologies and reagent coatings for various healthcare tests. Through its diversified business model, Surmodics strives to contribute to the advancement of medical care and improve patient outcomes.
Surmodics stock
Surmodics Peer Group
Surmodics Ticker
Surmodics FIGI
All fundamentals and in-depth analysis of Surmodics
Our stock analysis for Surmodics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Surmodics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.